Validated companion diagnostic offers rapid results and supports eligible patient selection for newly approved targeted therapy
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology testing services, today announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) assay. The test is now available to oncologists and pathologists nationwide, supporting treatment selection for patients with advanced non-small cell lung cancer (NSCLC) with a 48-hour turnaround time.
The c-MET CDx for NSCLC assay detects c-Met protein overexpression, a biomarker observed in up to 50% of patients with advanced NSCLC.¹ It is designed to help identify patients who may be eligible for newly approved targeted therapies, including EMRELIS™ (telisotuzumab vedotin-tllv), which was recently approved by the U.S. Food and Drug Administration (FDA).*
“Accurate and timely biomarker testing is critical in lung cancer, where targeted therapies can meaningfully change the course of a patient’s treatment,” said Dr. Nathan Montgomery, Vice President of Medical Services at NeoGenomics. “The c-MET CDx for NSCLC assay adds an important tool to our testing portfolio, helping oncologists quickly identify patients who may benefit from MET-directed therapies. It also complements our PanTracer™ suite, enabling comprehensive biomarker profiling for NSCLC.”
Key features of NeoGenomics’ assay include:
- Companion Diagnostic Indication: Developed in accordance with FDA guidance and validated for use with MET-targeted therapies.
- Fast Turnaround: Delivers results within 48 hours to enable timely, informed clinical decisions.
- Validated Performance: Designed for use with tumor tissue samples to detect MET protein overexpression.
- Integrated NSCLC Offering: Complements NeoGenomics’ broader PanTracer™ portfolio, including genomic and immuno-oncology markers.
The c-MET CDx for NSCLC assay is now available as part of NeoGenomics’ comprehensive NSCLC testing portfolio. Its addition supports the growing use of MET-directed therapies and reflects ongoing efforts to align diagnostic services with emerging standards in precision cancer care.
For more information or to order the test, visit www.neogenomics.com/cmetcdx.
*EMRELIS™ (telisotuzumab vedotin-tllv) was approved by the U.S. FDA on May 14, 2025, for adults with previously treated advanced NSCLC with high c-MET protein overexpression.
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!